CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

HUTCHMED jumps 15% after licensing cancer therapy to GSK for up to $1.295B

PartnershipPositive
AI Analysis

Summary

HUTCHMED licensed a cancer therapy to GSK for up to $1.295B in total consideration, resulting in a 15% stock price increase.

Outcome Details

Licensing deal with potential total consideration up to $1.295B

Importance:7/10
Sentiment:
0.85
licensingpartnershiponcologystock_movement
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on September 3, 2026 8:53 AM

Read Original